MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 10, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG

3,4-Methyl enedioxy methamphetamine

MDMA (3,4 methylenedioxymethamphetamine) is a synthetic, psychoactive drug that is chemically similar to the stimulant methamphetamine.

DRUG

Methamphetamine

Methamphetamine is a stimulant that affects the central nervous system. This is used as a control in the study.

BEHAVIORAL

Cognitive Behavioral Therapy (CBT)

Cognitive Behavioral Therapy with exposure and response prevention performed by therapist team.

Trial Locations (1)

94305

RECRUITING

Stanford University Medical Center, Palo Alto

All Listed Sponsors
lead

Carolyn Rodriguez

OTHER

NCT05783817 - MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) | Biotech Hunter | Biotech Hunter